 |
Top 10 Leukemia and Blood Cancer treatment startups in USA
Feb 21, 2025 | By Jason Kwon | 16 |
1
Funding: $223.9M
Senti is using the latest techniques in the fields to build the future of gene and cell-based therapies. Senti’s proprietary synthetic biology platform provides fundamental advantages for therapeutics development.
Senti is using the latest techniques in the fields to build the future of gene and cell-based therapies. Senti’s proprietary synthetic biology platform provides fundamental advantages for therapeutics development.
2
Funding: $414.8M
Abcuro develops first-in-class immunotherapies to treat autoimmunity and cancer.
Abcuro develops first-in-class immunotherapies to treat autoimmunity and cancer.
3
Funding: $3.4B
Bluebird Bio offers products based on the transformative potential of gene therapy for patients with genetic and orphan diseases.
Bluebird Bio offers products based on the transformative potential of gene therapy for patients with genetic and orphan diseases.
4
Funding: $1.2B
Kura Oncology, a biopharmaceutical company, advances a pipeline of precision medicines for the treatment of solid tumors and blood cancers.
Kura Oncology, a biopharmaceutical company, advances a pipeline of precision medicines for the treatment of solid tumors and blood cancers.
5
Funding: $622M
Arcellx develops intelligent and adaptive cell therapies to treat the complexity of human disease. It intends to provide cancer patients with first-in-class adaptive immune cell therapies that are readily silenced, activated, and reprogrammed throughout the course of disease.
Arcellx develops intelligent and adaptive cell therapies to treat the complexity of human disease. It intends to provide cancer patients with first-in-class adaptive immune cell therapies that are readily silenced, activated, and reprogrammed throughout the course of disease.
6
Funding: $146.5M
Imago BioSciences is working on a treatment that shuts down an enzyme important to blood cancer growth.
Imago BioSciences is working on a treatment that shuts down an enzyme important to blood cancer growth.
7
Funding: $135.7M
Amphivena Therapeutics develops treatments to address hematologic malignancies.
Amphivena Therapeutics develops treatments to address hematologic malignancies.
8
Funding: $120.5M
Nohla Therapeutics is a developing an shelf alternative to bone marrow transplants. Nohla is leading the development of universal, off-the-shelf cell therapies for patients with hematologic malignancies and other critical diseases.
Nohla Therapeutics is a developing an shelf alternative to bone marrow transplants. Nohla is leading the development of universal, off-the-shelf cell therapies for patients with hematologic malignancies and other critical diseases.
9
Funding: $75M
OncoMyx Therapeutics develops oncolytic immunotherapies to orchestrate an immune response and treat cancer.
OncoMyx Therapeutics develops oncolytic immunotherapies to orchestrate an immune response and treat cancer.
10
Funding: $74M
OncoImmune is a clinical-stage company that engages in the discovery and development of biopharmaceuticals for the treatment of cancer.
OncoImmune is a clinical-stage company that engages in the discovery and development of biopharmaceuticals for the treatment of cancer.
11
Funding: $54.8M
Notable Labs is a drug testing service to help oncologists identify actionable treatment options for people with blood cancers.
Notable Labs is a drug testing service to help oncologists identify actionable treatment options for people with blood cancers.
12
Funding: $15M
Kurome Therapeutics is developing therapies that target cancer cells that have co-opted immune signaling pathways in order to avoid destruction by traditional therapeutic agents and subvert adaptive resistance mechanisms. The first goal is to to treat acute myeloid leukemia (AML) by targeting adaptive resistance mechanisms.
Kurome Therapeutics is developing therapies that target cancer cells that have co-opted immune signaling pathways in order to avoid destruction by traditional therapeutic agents and subvert adaptive resistance mechanisms. The first goal is to to treat acute myeloid leukemia (AML) by targeting adaptive resistance mechanisms.
